Who is sponsoring NCT05527275?

NCT05527275 is sponsored by Sun Yat-sen University.

What drugs are being tested in NCT05527275?

Interventions in NCT05527275: Mitoxantrone liposome combine with Chidamide.

What condition does NCT05527275 study?

NCT05527275 studies Relapsed and Refractory Peripheral T-cell Lymphoma.

Is NCT05527275 still recruiting?

NCT05527275 is currently status unknown. Last updated 2 September 2022.

Last reviewed 2022-09-02 · How we verify

NCT05527275

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Phase I/II Study of Mitoxantrone Liposome Combined With Chidamide in Relapsed/Refractory Peripheral T-cell Lymphoma

Status unknown Phase 1, PHASE2 Last updated 2 September 2022

What this trial tests

Phase 1, PHASE2 trial testing Mitoxantrone liposome combine with Chidamide in Relapsed and Refractory Peripheral T-cell Lymphoma in 78 participants. Status unknown.

Timeline

1 October 2022

Primary endpoint
1 September 2024

1 December 2024

Quick facts

Lead sponsor	Sun Yat-sen University
Phase	Phase 1, PHASE2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	78
Start date	1 October 2022
Primary completion	1 September 2024
Estimated completion	1 December 2024
Sites	1 location across China

Drugs / interventions tested

Mitoxantrone liposome combine with Chidamide — full drug profile →

Conditions studied

Relapsed and Refractory Peripheral T-cell Lymphoma — all drugs for Relapsed and Refractory Peripheral T-cell Lymphoma →

Sponsor

Sun Yat-sen University

Who can join

Adults 18 to 70, any sex, with Relapsed and Refractory Peripheral T-cell Lymphoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Peripheral T-cell lymphoma (PTCL) is a highly heterogeneous group of aggressive non-Hodgkin lymphoma (NHL) originating from mature thymus T cells.Mitoxantrone Hydrochloride Liposome Injection can accelerate the entry of mitoxantrone into cells, reduce the efflux of mitoxantrone, ensure the concentration of intracellular drugs, reverse the drug resistance mechanism, and enhance anti-tumor activity.We will explore the dose-limiting toxicity (DLT) of Mitoxantrone Hydrochloride Liposome Injection combined with Chidamide in the treatment of relapsed or refractory peripheral T-cell lymphoma, estimate the maximum tolerated dose (MTD) of the combination, and determine the phase II recommended dose RP2D.In the phase II study, we will evaluate the safety and efficacy of the combination regimen.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Case report: Good response to CMOP regimen containing mitoxantrone hydrochloride liposome (PLM60) as induction chemotherapy in patients with angioimmunoblastic T-cell lymphoma.
Liang L, Jiang M. · · 2024 · cited 1× · PMID 38357199 · DOI 10.3389/fonc.2024.1331154
Publication Only
· 2025

Verify or expand the search:

Other Sun Yat-sen University trials

Trials by the same sponsor.

NCT07255612 — Bone Marrow Protection, Safety, Efficacy of Trilaciclib and Eribulin in Locally Advanced or Metastatic TNBC(Triple-negat · Phase 2 · not yet recruiting
NCT07371897 — Toripalimab ± Chemo as Neoadjuvant Therapy in LA-HNSCC: A Phase III Trial · Phase 3 · not yet recruiting
NCT07489703 — SHR-A1811 + AK112 in HER2-Altered Advanced/Metastatic NSCLC · Phase 2 · not yet recruiting
NCT07528209 — Neoadjuvant CAPOX With or Without Pucotenlimab Plus Selective Radiotherapy for Locally Advanced Rectal Cancer · Phase 3 · recruiting
NCT07522281 — Evaluation of an Undisturbed Embryo Culture System for Embryo Development in IVF/ICSI Cycles · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05527275 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Sun Yat-sen University
Last refreshed: 2 September 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05527275.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing